On September 7, 2021 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021 (Press release, Aileron Therapeutics, SEP 7, 2021, View Source [SID1234587298]). Dr. Aivado’s presentation will include an update on the company’s progress advancing ALRN-6924 as a selective chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An on-demand corporate presentation will be accessible to registered conference attendees starting on Monday, September 13, 2021 at 7 am ET. A recorded webcast of the presentation will be archived under the Investors and Media section of Aileron’s website at View Source for 30 days following the event. Aileron management will conduct one-on-one meetings with investors during the conference.

On September 7, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences (Press release, Kura Oncology, SEP 7, 2021, View Source [SID1234587315]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 13, 2021; and

A pre-recorded fireside chat at the Cantor Global Healthcare Conference, available at 3:20 p.m. ET / 12:20 p.m. PT on September 27, 2021.
Audio webcasts of the H.C. Wainwright and Cantor events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

On September 7, 2021 Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, reported the company will participate in three investor conferences in September 2021 (Press release, Sierra Oncology, SEP 7, 2021, View Source [SID1234587331]). Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit. He will participate in a fireside chat discussion at the 2021 Cantor Virtual Global Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Conference: HC Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: On demand viewing beginning at 7:00 am ET

Conference: Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Date: Tuesday, September 21, 2021
Time: Presentation beginning at 2:05 pm ET

Conference: 2021 Cantor Virtual Global Healthcare Conference
Date: Tuesday, September 28, 2021
Time: Fireside chat beginning at 4:00 pm ET
All three presentations will be webcast and available at the times noted above on the Investors section of Sierra’s corporate website in the Events & Webcast tab.

On September 7, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported it will be participating in two upcoming virtual investor conferences (Press release, Lantern Pharma, SEP 7, 2021, View Source [SID1234587347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Colliers Institutional Investor Conference
Panna Sharma, President & CEO of Lantern Pharma, will be hosting one-on-one meetings at the 2021 Colliers Institutional investor conference being held virtually September 9-10, 2021. Investors interested in arranging a meeting should contact their Collier sales representative.

H.C. Wainwright 23rd Annual Global Investment Conference
Mr. Sharma will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Lantern’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Lantern’s website at View Source Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

On September 7, 2021 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported that its management team will present at the following healthcare conferences (Press release, Savara, SEP 7, 2021, View Source [SID1234587364]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET / 4:00 AM PT on September 13, 2021.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of the presentation will take place at 12:25 PM ET / 9:25 AM PT on September 20, 2021.
Both webcast presentations will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.